Differentiation between vasogenic-edema versus tumor-infiltrative area in patients with glioblastoma during bevacizumab therapy: a longitudinal MRI study.

BACKGROUND Treatment with bevacizumab is associated with substantial radiologic response in patients with glioblastoma (GB). However, following this initial response, changes in T2-weighted MRI signal may develop, suggesting an infiltrative pattern of tumor progression. The aim of this study was to differentiate between vasogenic-edema versus tumor-infiltrative area in GB patients. METHODS AND MATERIALS Fourteen patients with GB were longitudinally scanned, before and during intravenous bevacizumab therapy (5/10mg/kg every 2-weeks). A total of 40 MR scans including conventional, diffusion, dynamic susceptibility contrast, dynamic contrast enhancement imaging, and MR-spectroscopy (MRS) were analyzed. Classification of non-enhancing fluid-attenuation-inversion-recovery (FLAIR) area was performed based on mean diffusivity, cerebral blood volume and flow maps, and further characterized using multiple MRI parameters. RESULTS The non-enhancing FLAIR lesion area was classified into: vasogenic-edema, characterized by reduced perfusion and increased FLAIR values; or tumor-infiltrative area, characterized by increased perfusion. Tumor-infiltrative area demonstrated a higher malignant pattern on MRS compared to areas of vasogenic-edema. Substantial reductions of the enhanced T1-weighted (58 ± 10%) and hyperintense FLAIR (53 ± 9%) lesion volumes were detected mainly during the first weeks of therapy, with a shift to an infiltrative pattern of tumor progression thereafter, as detected by an increase in tumor-infiltrative area in the majority of patients, which correlated with progression-free survival (week 8: r=-0.86, p=0.003, week 16: r=-0.99, p=0.001). CONCLUSION Characterization of non-enhancing hyperintense FLAIR lesion area in GB patients can provide an MR-based biomarker, indicating a shift to an infiltrative progression pattern, and may improve therapy response assessment in patients following bevacizumab therapy.

[1]  K. Oguz,et al.  Dynamic contrast-enhanced susceptibility-weighted perfusion imaging of intracranial tumors: a study using a 3T MR scanner. , 2009, Diagnostic and interventional radiology.

[2]  Alan C. Evans,et al.  A nonparametric method for automatic correction of intensity nonuniformity in MRI data , 1998, IEEE Transactions on Medical Imaging.

[3]  T. Mikkelsen,et al.  Correlation between Magnetic Resonance Spectroscopy Imaging and Image-guided Biopsies: Semiquantitative and Qualitative Histopathological Analyses of Patients with Untreated Glioma , 2001, Neurosurgery.

[4]  Alan L. Yuille,et al.  Efficient Multilevel Brain Tumor Segmentation With Integrated Bayesian Model Classification , 2008, IEEE Transactions on Medical Imaging.

[5]  B. Hakyemez,et al.  Glioblastoma multiforme with atypical diffusion-weighted MR findings. , 2005, The British journal of radiology.

[6]  T. Goto,et al.  Diffusion tensor-based tumor infiltration index cannot discriminate vasogenic edema from tumor-infiltrated edema , 2010, Journal of Neuro-Oncology.

[7]  Michael Weller,et al.  Standards of care for treatment of recurrent glioblastoma--are we there yet? , 2013, Neuro-oncology.

[8]  K. Hossmann,et al.  Blood Flow and Regulation of Blood Flow in Experimental Peritumoral Edema , 1981, Stroke.

[9]  P. Tofts,et al.  Measurement of the blood‐brain barrier permeability and leakage space using dynamic MR imaging. 1. Fundamental concepts , 1991, Magnetic resonance in medicine.

[10]  Michal Neeman,et al.  In Vivo Prediction of Vascular Susceptibility to Vascular Endothelial Growth Factor Withdrawal Magnetic Resonance Imaging of C6 Rat Glioma in Nude Mice , 1999 .

[11]  Albert Lai,et al.  Quantification of edema reduction using differential quantitative T2 (DQT2) relaxometry mapping in recurrent glioblastoma treated with bevacizumab , 2011, Journal of Neuro-Oncology.

[12]  Harumi Itoh,et al.  Peritumoral brain edema in intracranial meningiomas evaluated by dynamic perfusion-weighted MR imaging: a preliminary study , 2003, European Radiology.

[13]  Stephen M. Smith,et al.  Segmentation of brain MR images through a hidden Markov random field model and the expectation-maximization algorithm , 2001, IEEE Transactions on Medical Imaging.

[14]  Ann M. Peiffer,et al.  Radiation-induced brain injury: A review , 2012, Front. Oncol..

[15]  Glyn Johnson,et al.  High-grade gliomas and solitary metastases: differentiation by using perfusion and proton spectroscopic MR imaging. , 2002, Radiology.

[16]  T. Mikkelsen,et al.  Rebound tumour progression after the cessation of bevacizumab therapy in patients with recurrent high-grade glioma , 2010, Journal of Neuro-Oncology.

[17]  Santosh Kesari,et al.  Malignant gliomas in adults. , 2008, The New England journal of medicine.

[18]  G. Fuller,et al.  Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice , 2010, Neuro-oncology.

[19]  Jacob Cohen,et al.  A power primer. , 1992, Psychological bulletin.

[20]  C. Vecht,et al.  The management of brain edema in brain tumors , 2004, Current opinion in oncology.

[21]  Dafna Ben Bashat,et al.  Automatic multi-modal MR tissue classification for the assessment of response to bevacizumab in patients with glioblastoma. , 2013, European journal of radiology.

[22]  D. McDonald,et al.  Rapid vascular regrowth in tumors after reversal of VEGF inhibition. , 2006, The Journal of clinical investigation.

[23]  Alina Jurcoane,et al.  Quantitative T2 mapping of recurrent glioblastoma under bevacizumab improves monitoring for non-enhancing tumor progression and predicts overall survival. , 2013, Neuro-oncology.

[24]  Christopher Nimsky,et al.  A Flexible Semi-Automatic Approach for Glioblastoma multiforme Segmentation , 2011, ArXiv.

[25]  M. Frosch,et al.  Diffusion magnetic resonance imaging detects pathologically confirmed, nonenhancing tumor progression in a patient with recurrent glioblastoma receiving bevacizumab. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  Jonathan R. Young,et al.  Advances in MRI Assessment of Gliomas and Response to Anti-VEGF Therapy , 2011, Current neurology and neuroscience reports.

[27]  Usha Sinha,et al.  Relationships Between Choline Magnetic Resonance Spectroscopy, Apparent Diffusion Coefficient and Quantitative Histopathology in Human Glioma , 2000, Journal of Neuro-Oncology.

[28]  Dafna Ben Bashat,et al.  FLAIR lesion segmentation: application in patients with brain tumors and acute ischemic stroke. , 2013, European journal of radiology.

[29]  Glyn Johnson,et al.  Diffusion-tensor MR imaging of intracranial neoplasia and associated peritumoral edema: introduction of the tumor infiltration index. , 2004, Radiology.

[30]  Susan M. Chang,et al.  Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.